175 related articles for article (PubMed ID: 32978170)
1. EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway.
Chen HN; Liang KH; Lai JK; Lan CH; Liao MY; Hung SH; Chuang YT; Chen KC; Tsuei WW; Wu HC
Cancer Res; 2020 Nov; 80(22):5035-5050. PubMed ID: 32978170
[TBL] [Abstract][Full Text] [Related]
2. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells.
Liang KH; Tso HC; Hung SH; Kuan II; Lai JK; Ke FY; Chuang YT; Liu IJ; Wang YP; Chen RH; Wu HC
Cancer Lett; 2018 Oct; 433():165-175. PubMed ID: 29981429
[TBL] [Abstract][Full Text] [Related]
3. Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis.
Lee CC; Yu CJ; Panda SS; Chen KC; Liang KH; Huang WC; Wang YS; Ho PC; Wu HC
J Transl Med; 2023 Aug; 21(1):530. PubMed ID: 37543570
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
[TBL] [Abstract][Full Text] [Related]
7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
8. Fluid shear stress suppresses TNF-α-induced apoptosis in MC3T3-E1 cells: Involvement of ERK5-AKT-FoxO3a-Bim/FasL signaling pathways.
Bin G; Bo Z; Jing W; Jin J; Xiaoyi T; Cong C; Liping A; Jinglin M; Cuifang W; Yonggang C; Yayi X
Exp Cell Res; 2016 May; 343(2):208-217. PubMed ID: 27060196
[TBL] [Abstract][Full Text] [Related]
9. EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers.
Pan M; Schinke H; Luxenburger E; Kranz G; Shakhtour J; Libl D; Huang Y; Gaber A; Pavšič M; Lenarčič B; Kitz J; Jakob M; Schwenk-Zieger S; Canis M; Hess J; Unger K; Baumeister P; Gires O
PLoS Biol; 2018 Sep; 16(9):e2006624. PubMed ID: 30261040
[TBL] [Abstract][Full Text] [Related]
10. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
11. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
13. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
15. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8
Liu X; Wu X; Cao S; Harrington SM; Yin P; Mansfield AS; Dong H
Sci Rep; 2016 Nov; 6():36722. PubMed ID: 27824138
[TBL] [Abstract][Full Text] [Related]
16. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
Chen M; Sharma A; Lin Y; Wu Y; He Q; Gu Y; Xu ZP; Monteiro M; Gu W
BMC Cancer; 2019 Feb; 19(1):153. PubMed ID: 30770752
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
Song X; Shao Y; Jiang T; Ding Y; Xu B; Zheng X; Wang Q; Chen X; Gu W; Wu C; Jiang J
EBioMedicine; 2018 Feb; 28():105-113. PubMed ID: 29396299
[TBL] [Abstract][Full Text] [Related]
18. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
[TBL] [Abstract][Full Text] [Related]
19. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
20. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
